Medical Device Investing Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
Medical Device Investing Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
Medical Device Investing Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
Medical Device Investing Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
Medical Device Investing Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635
Medical Device Investing Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule Study
Nextech3D.ai Reports Strong 20% Q2 Sequential Revenue Growth With Gross Margins of 88% For the Three Months Ended September 30, 2025 ("Q2 2026")
